{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0"},{"groupId":"OG001","value":"100.0"},{"groupId":"OG002","value":"66.7"},{"groupId":"OG003","value":"75.0"}]}],"title":"Day 5 (total= 1, 2, 15, 4)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0"},{"groupId":"OG001","value":"100.0"},{"groupId":"OG002","value":"72.7"},{"groupId":"OG003","value":"75.0"}]}],"title":"Day 8 (total = 1, 3, 11, 4)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"comment":"No patients were analyzed for this arm.","groupId":"OG001","value":"NA"},{"comment":"No patients were analyzed for this arm.","groupId":"OG002","value":"NA"},{"comment":"No patients were analyzed for this arm.","groupId":"OG003","value":"NA"}]}],"title":"End of Study (total=1, 0, 0, 0)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"5"}],"units":"Participants"}],"groups":[{"description":"Panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF)","id":"OG000","title":"Arm 1, Group Y (20 mg)"},{"description":"Panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF)","id":"OG001","title":"Arm 1, Group Y (30 mg)"},{"description":"Panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF)","id":"OG002","title":"Arm 1, Group Y (40 mg)"},{"description":"Panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF)","id":"OG003","title":"Arm 1, Group Y (60 mg)"}],"paramType":"NUMBER","populationDescription":"Full Analysis Set","reportingStatus":"POSTED","timeFrame":"Days 5, 8, end of study (up to 3.5 years)","title":"Percentages of Participants With Histone Acetylation Induction in Peripheral Blood in Arm 1 (MWF Every Week), Group Y","type":"SECONDARY","unitOfMeasure":"Percentages of participants"}